{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:03Z","timestamp":1760146863318},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/mph.0b013e3181cf0726","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T07:36:29Z","timestamp":1277796989000},"page":"e167-e172","source":"Crossref","is-referenced-by-count":18,"title":["Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome"],"prefix":"10.1097","volume":"32","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Verhulst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore J.","family":"Bertolone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Bhatla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lebowizc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon K.","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210227","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"R2-21-20210227","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2006.12.038","article-title":"Treatment with rituximab in benign and malignant hematologic disorders in children","volume":"205","author":"Guilino","year":"2007","journal-title":"J Pediatr"},{"key":"R3-21-20210227","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"R4-21-20210227","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.20125","article-title":"CSF B cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity","volume":"19","author":"Pranzatelli","year":"2004","journal-title":"Mov Disord"},{"key":"R5-21-20210227","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mpo.1139","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features\u2014a report from the children's cancer group","volume":"36","author":"Cooper","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R6-21-20210227","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","article-title":"Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome","volume":"28","author":"Pranzatelli","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"R7-21-20210227","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/pbc.20899","article-title":"Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus","volume":"50","author":"Bell","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R8-21-20210227","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/08880010802341690","article-title":"Response to rituximab and prednisone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma","volume":"25","author":"Corapcioglu","year":"2008","journal-title":"Pediatr Hematol Oncol"},{"key":"R9-21-20210227","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pediatrneurol.2008.05.015","article-title":"Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome","volume":"39","author":"Leen","year":"2008","journal-title":"Pediatr Neurol"},{"key":"R10-21-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199619010-00001","article-title":"The immunopharmacology of the opsoclonus-myoclonus syndrome","volume":"19","author":"Pranzatelli","year":"1996","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"R11-21-20210227","first-page":"S113","article-title":"Pharmacokinetic and time-course study of rituximab in pediatric opsoclonus-myoclonus syndrome","volume":"62","author":"Tate","year":"2007","journal-title":"Ann Neurol"},{"key":"R12-21-20210227","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mds.870130323","article-title":"Monoaminergic effects of high dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus","volume":"13","author":"Pranzatelli","year":"1998","journal-title":"Mov Disord"},{"key":"R13-21-20210227","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200006000-00010","article-title":"Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study","volume":"22","author":"Iacona","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R14-21-20210227","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","article-title":"Pharmacokinetics of rituximab and its clinical use: thought for the best use?","volume":"62","author":"Cartron","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"R15-21-20210227","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"The Drug Monit"},{"key":"R16-21-20210227","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkins lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"R17-21-20210227","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R18-21-20210227","first-page":"1243","article-title":"Pharmacokinetics (PK) substudy of rituximab in a prospective clinical trial for pediatric chronic immune thrombocytopenic purpura (cITP).","volume":"106","author":"Bennett","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R19-21-20210227","first-page":"1006","article-title":"Rituximab for refractory childhood autoimmune hemolytic anemia","volume":"4","author":"Motto","year":"2002","journal-title":"IMAJ"},{"key":"R20-21-20210227","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Investigational New Drugs"},{"key":"R22-21-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","article-title":"Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders","volume":"15","author":"Petereit","year":"2009","journal-title":"Mult Scler"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0b013e3181cf0726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:06:59Z","timestamp":1620965219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201007000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3181cf0726","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}